v3.26.1
Stockholders' Equity
 9 Months Ended
Jul. 31, 2026
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
Note 8. Stockholders' Equity
Analysis of Changes in Accumulated Other Comprehensive Loss:
(In millions)Foreign Currency Translation AdjustmentMinimum Pension LiabilityDerivative InstrumentsTotal
Balance at October 31, 2024$(461.7)$(4.9)$44.9 $(421.7)
Gross change in value47.3 — (23.4)23.9 
Tax effect— — 5.7 5.7 
Balance at July 31, 2025$(414.4)$(4.9)$27.2 $(392.1)
Balance at October 31, 2025$(426.2)$1.7 $18.0 $(406.5)
Gross change in value28.4 — (6.7)21.7 
Tax effect— — 1.6 1.6 
Balance at July 31, 2026$(397.8)$1.7 $12.9 $(383.2)
Share Repurchases
In September 2025, the authorization under the 2012 Share Repurchase Program was increased to $2.0 billion by the Company's Board of Directors. As of July 31, 2026, $521.7 million remains authorized for repurchase. Subsequent to the fiscal quarter ended July 31, 2026, the Company's Board of Directors approved an additional increase in the share repurchase authorization. Refer to Note 12. Subsequent Event for additional information.
During the three and nine months ended July 31, 2026, the Company repurchased 4.9 million and 6.2 million shares of its common stock for $339.1 million and $444.7 million, at a weighted average price of $69.16 and $71.69 per share, respectively. During the three and nine months ended July 31, 2025, the Company repurchased 0.7 million and 1.2 million shares of its common stock for $52.2 million and $92.8 million, at a weighted average price of $71.97 and $73.51 per share, respectively.